SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A

SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A

CORONAVIRUS COVID-19 TREATMENT

Canada (ACCESSWIRE) Sunshine Biopharma Inc. (OTC

Pink Sheets: SBFM ), a pharmaceutical company focused

on the research, development and commercialization of drugs for the

treatment of aggressive forms of cancer today announced that it has

filed a patent application in the United States for a new treatment

for Coronavirus infections, including COVID-19. Sunshine's

patent application covers composition subject matter pertaining to

small molecules for inhibition of the main Coronavirus protease

(Mpro), an enzyme that is essential for viral replication. The

small molecules covered by the patent application were computer

modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine

Biopharma. The patent application has a priority date of May 22,

causative agent of the current COVID-19 global pandemic is Severe

Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), one of

several strains of Coronavirus capable of infecting humans and

causing serious illness. SARS-CoV-2 produces several functional

proteins in infected human cells by cleaving them from two

overlapping viral polyproteins,' pp1a and pp1ab. One

of these functional proteins is a cysteine protease referred to as

the main protease (Mpro, also called 3CLpro and nsp5). Mpro cleaves

the viral polyproteins' at a number of specific sites

thereby generating a multi-subunit protein complex termed

viral replicase-transcriptase'. Because of its

functional indispensability in viral replication, Mpro is an

attractive drug target for the development of a treatment for

COVID-19 and other Coronavirus infections, said Dr.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not

strictly historical, including statements as to revenue

projections, business strategy, outlook, objectives, future

milestones, plans, intentions, goals, future financial conditions,

future collaboration agreements, the success of the Company's

development, events conditioned on stockholder or other approval,

or otherwise as to future events, such statements are

forward-looking, and are made pursuant to the safe harbor

provisions of the Private Securities Litigation Reform Act of 1995.

The forward-looking statements contained in this release are

subject to certain risks and uncertainties that could cause actual

results to differ materially from the statements made.

For Additional Information:

Sunshine Biopharma, Inc.